India ID Exchange · Board Seats
Risk Committee Chair Roles in Healthcare and Pharma Industry in Bengaluru
Risk chair roles on Bengaluru healthcare boards—covering patient safety, quality, digital systems, clinical evidence and critical supply resilience.
Bengaluru healthcare risk increasingly crosses the clinical-digital boundary. The chair must test how software, data and vendors change patient consequence without allowing responsibility to fall between expert teams.
- Seats on this page
- 1
- Open now
- 0
- Forecast to open
- 38
- Boards read daily
- 3,790
Company identity, per-firm fees, deadline and the full brief remain Foresight-only.
The seats
What is live now, what the filings suggest is approaching, and what changed on tracked boards.
Open risk committee chair seats—Bengaluru healthcare and pharma
The live board recognises RMC and Risk committee text in granular mandates. The census uses the filings' RMC key, avoiding the silent-zero trap.
On the horizon
(1)Appointment expected in 91–180 days.
Board Advisor — PE-Backed Women’s Health Platform
Long Term — seat in ~6 monthsBoard Advisor · Healthcare & Life Sciences · Bengaluru · Initial 24 months, renewable by mutual agreement
Clinical QualityRiskInvestmentView seat & applyDirect Gladwin mandate · 22–28 days a year, including clinical-quality reviews, acquisition assessments and operating visits
How applying works
- 01
Open the seat
The full brief, committee load and term sit on the seat's own page.
- 02
Apply
One click from the seat page. No cover letter, no chasing an intermediary.
- 03
Create your profile
Register if you are new, then add your CV and directorship details once.
- 04
Applied — and matched
Your profile stays live, so the next matching seat reaches you first.
Same seat, other cities (5)
risk committee chair seats in this sector outside Bengaluru. Board seats rarely require relocation — most carry four to six meetings a year.
Hospitals — Independent Director, Clinical Capacity and Capital Accountability
Urgent — Priority appointmentIndependent Director · Women's, Children's & Family Hospital Services · Jaipur · Initial term subject to applicable law, appointment process and shareholder approval where required
RiskClinical Quality & EthicsInvestmentView seat & applyDirect Gladwin mandate · 26–32 days annually
Healthcare Technology — Independent Director, Medication Safety and Clinical Pharmacy Systems
Urgent — Priority appointmentIndependent Director · Medication Safety, Clinical Pharmacy Systems & Health Informatics · Hyderabad · Initial term subject to applicable law, appointment process and shareholder approval where required
AuditRiskClinical TechnologyView seat & applyDirect Gladwin mandate · Approximately 24–30 days annually
Independent Director — Institutional Medicines Supply and Distribution | Finance Function, Inventory Integrity and Credit Governance
Medium Term — seat in ~3 monthsIndependent Director · Pharmaceutical Distribution & Institutional Medicine Supply · Kolkata · Initial term subject to applicable law, appointment process and shareholder approval where required
Audit (Chair)Finance & RiskView seat & applyDirect Gladwin mandate · 24–30 days annually, including warehouse and distribution reviews
Non-Executive Director — Biomedical Waste Treatment and Healthcare Environmental Services Company | Chain of Custody, Infection Risk and Environmental Compliance
Medium Term — seat in ~3 monthsNon-Executive Director · Biomedical-Waste Collection, Treatment & Healthcare Environmental Services · Kochi · Subject to the company's Articles, shareholder process, applicable permissions and Board approval
AuditRiskSafety, Environment & OperationsView seat & applyDirect Gladwin mandate · 22–28 days annually, including collection-route, treatment-facility and downstream-destination visits
Independent Director — PE-Backed Occupational Health and Workforce Medical Services | Clinical Independence, Employer Contracts and Integration
Medium Term — seat in ~3 monthsIndependent Director · Occupational Health, Workforce Medical Services & Employer Wellness · Hyderabad · Three years, subject to shareholder approval and annual independence review
AuditRiskClinical Quality & EthicsView seat & applyDirect Gladwin mandate · Approximately 24–30 days annually, including clinical and workplace-service visits
Other committees in Bengaluru (1)
Open seats on the same sector’s boards in Bengaluru, on committees other than the risk committee chair.
Independent Director — IPO-Stage Companion Animal Care Network | Clinical Quality, Ethical Growth and Network Integration
Medium Term — seat in ~3 monthsIndependent Director · Companion-Animal Hospitals, Clinics & Care Services · Bengaluru · Initial term subject to applicable law, appointment process and shareholder approval where required
AuditClinical Quality & EthicsView seat & applyDirect Gladwin mandate · Approximately 28–34 days annually through IPO readiness and the first listed reporting cycle
What is hidden on the 7 seats above
- · The company behind each mandate, where it has authorised disclosure
- · Sitting fees, committee fees and annual retainer — always members-only
- · The application deadline and the full mandate brief
- · Direct application, without waiting for a seat to open to free members
Risk Committee Chair Roles in Healthcare and Pharma Industry in Bengaluru is a narrow, high-competition shape. Foresight members apply the day a seat is posted, up to ten a day; free members wait for the deadline window and a cap of one application a week. On a shortlist of five, that timing is the contest.
Unlock with ForesightSeats forecast to reach a term boundary
The latest filings record 168 sitting chairs in this cohort. The counts below are term-boundary signals, not announced vacancies; reappointments and early exits can move the date.
20
First term completing
Four to five years served; the board can renew or reopen the skills question.
1
Second term completing
Nine to ten years served; a further consecutive term is unavailable.
17
Past ten years
A succession signal that requires examination, not a claim about any named director.
Board movements in the latest filing period
Exchange filings for Jun 2026 recorded 62 appointments and 54 departures in this page’s measured market. These are filed movements, not inferred vacancies.
| Movement | Board | Director | Filed category |
|---|---|---|---|
| Appointed | Cipla Limited | Achin Gupta | Executive Director |
| Departed | Cipla Limited | Umang Vohra | Executive Director |
| Appointed | Sun Pharmaceutical Industries Limited | Satyavati Berera | Non-Executive - Independent Director |
| Appointed | Sun Pharmaceutical Industries Limited | Andreas Busch | Non-Executive - Independent Director |
| Appointed | Abbott India Limited | Neeraj Jain | Non-Executive - Independent Director |
| Appointed | Abbott India Limited | James Wenner | Non-Executive - Non Independent Director |
| Appointed | GlaxoSmithkline Pharmaceticuals Limited | Ronojit Biswas | Executive Director |
| Appointed | SANOFI INDIA LIMITED | Siraj Chaudhry | Non-Executive - Independent Director |
| Appointed | SANOFI INDIA LIMITED | Rajani Kesari | Non-Executive - Independent Director |
| Appointed | NEULAND LABORATORIES LIMITED | Mauricio Futran | Non-Executive - Non Independent Director |
The market
The incumbent pool, term pattern, concentration, committee resilience, representation and disclosed pay.
Who holds this seat today
The aggregate healthcare RMC cohort provides measured tenure, floor and representation evidence without identifying individual directors.
168
Sitting chairs
1
Median listed boards
18%
Holding 3+ boards
4.4 : 1
Incumbents / boundary
Tenure profile
15
Appointments in 12 months
Filed arrivals only; cessation data is not populated well enough to publish reasons for departure.
8.9%
Observed arrival rate
This is not converted into an implied tenure; that inference conflicts with the measured histogram.
66.7%
Newcomers on one board
Capacity, not an already-large portfolio, is visible in the newly appointed cohort.
Where the incumbent seats sit by company size
The governance dataset carries one flat sector label, so this block uses disclosed market-cap bands. It does not invent bank, software or pharma sub-sectors that the filings do not contain.
Committee floor and representation
33.3%
At the three-member floor
0
Below three members in the filing
20%
Women among recorded chairs, versus 25.1% of members
What the seat pays
Public bands answer the market question without exposing the company-specific figure. The rows below are computed from 234 annual-report records; each denominator is shown.
| Benchmark | P25 | Median | P75 | P90 |
|---|---|---|---|---|
| Board meeting n=50 | ₹25,000 | ₹50,000 | ₹1 lakh | ₹1 lakh |
| Committee meeting n=43 | ₹25,000 | ₹50,000 | ₹1 lakh | ₹1 lakh |
| Annual per ID n=58 | ₹1.5 lakh | ₹4 lakh | ₹12.8 lakh | ₹30 lakh |
| Highest-paid ID n=58 | ₹2 lakh | ₹5.2 lakh | ₹18 lakh | ₹30 lakh |
Ranges across companies, not offers. Per-company fees remain gated on each seat’s own detail page.
Open the ID salary benchmarkThe seat itself
The work behind the title, the sector-specific judgement it requires, and the evidence a nomination committee will test.
What the role actually owns
Appetite
Risk appetite
Turn the board's strategy into explicit tolerances, triggers and escalation rights that management can actually operate.
Resilience
Stress and scenario testing
Choose severe but plausible scenarios, test management action and expose where liquidity, operations or trust fail first.
Foresight
Emerging-risk radar
Bring cyber, third-party, model, regulatory and concentration risks onto one decision agenda before they become incident reports.
Response
Crisis governance
Pre-agree who decides, what reaches the board and how facts are verified when minutes matter more than presentation polish.
Why healthcare risk begins with patient consequence
Quality, clinical, supply, pharmacovigilance, data and market-access risks converge on patients before they converge on a financial dashboard. The chair must make weak signals visible without turning technical experts into presenters of false certainty.
Quality
Quality risk is systemic
A deviation can expose supplier, batch, site, data-integrity and culture failures together.
Continuity
Supply resilience has clinical impact
Single-source ingredients, cold chain and specialist capacity can turn an operating disruption into interrupted care.
Signals
Evidence changes over time
Trial, safety and real-world signals require escalation rules that tolerate uncertainty while protecting patients.
Do you qualify for this seat?
The board needs a chair who can ask decision-grade questions of scientists, clinicians, quality leaders and operators without diluting their accountability.
01 · Purpose
Patient-first risk judgement
Frame appetite and escalation around safety and continuity before financial recovery.
02 · Quality
Quality-system literacy
Understand deviation, investigation, CAPA, change control and data-integrity evidence.
03 · Clinical
Clinical and safety governance
Challenge signal detection, protocol deviation and decision authority under uncertainty.
04 · Supply
Supply-chain resilience
Test concentration, cold chain, alternate qualification and stock strategy for critical products.
05 · Trust
Regulatory communication
Show transparent escalation with CDSCO or global regulators while facts are still developing.
06 · Capacity
Crisis capacity
Be available for recall, safety, cyber or facility events between planned meetings.
Doing the job
The dated obligations, the first hundred days, and a practical checklist for the work behind the appointment.
The regulatory year
Healthcare risk oversight replaces the RBI row with product-quality, clinical, safety and data obligations under the applicable Indian framework.
First board meeting of the year
Companies Act s.149(7)
Record each independent director's declaration and test conflicts against the current group structure, not last year's chart.
At least once each financial year
Applicable LODR committee regulation
Meet the statutory minimum, but schedule decisions when the evidence is available; an annual formality is not active oversight.
Annual independent-director meeting
LODR Reg. 25(3)
Use the session without management to surface information gaps and agree what must return to the full board.
Before the annual evaluation
LODR Schedule II
Set evaluation criteria before scoring begins and preserve the evidence behind difficult conclusions.
By 30 September
MCA DIR-3 KYC
Confirm every DIN remains active. Administrative lapse can disable a director at the point a committee most needs continuity.
At annual product-quality and enterprise-risk review
Drugs and Cosmetics / CDSCO quality framework
Connect recurring deviations, supplier risk, data integrity and CAPA effectiveness to appetite and investment.
On a material safety, quality or trial signal
NDCTR and pharmacovigilance obligations
Verify patient protection, accountable decision rights, regulator communication, evidence preservation and independent closure.
Provision summaries are orientation, not legal advice. Verify the current Act, Listing Regulations and sector direction before relying on an item.
Your first hundred days
The opening agenda should establish which weak signals reach the board, who may stop activity and how recovery is independently proven.
Days 1–15
Map patient-critical processes
Identify sites, products, trials, data and suppliers whose failure creates immediate patient consequence.
Days 15–30
Read repeat deviations
Look past closure counts to recurring root causes, overdue CAPA and management overrides.
Days 30–45
Test stop authority
Confirm who can halt release, manufacturing, enrolment or promotion and how escalation bypasses commercial pressure.
Days 45–60
Stress the supply chain
Model loss of a critical input, site, cold-chain lane or specialist service with realistic qualification time.
Days 60–80
Run a safety escalation
Trace a changing signal from detection through medical judgement, regulator contact and board decision.
Days 80–100
Reset risk indicators
Lead with recurrence, ageing, patient exposure, control reliability and recovery evidence—not activity volume.
Questions directors actually ask
Must a healthcare risk chair be a clinician?
No. Clinical experience can help, but the chair must govern expert evidence, patient consequence, escalation and resilience across the enterprise.
How is quality risk different from compliance?
Compliance asks whether requirements are met. Quality risk asks how process, data, culture and supplier weaknesses can harm a patient or invalidate evidence.
What replaces the RBI regulatory row?
CDSCO, drugs-and-cosmetics, clinical-trial and pharmacovigilance duties create the relevant sector layer.
Does supply risk belong at board level?
It does when concentration, qualification time or cold-chain failure can interrupt critical products or materially affect patients and the business.
Are forecast counts guaranteed openings?
No. They are aggregate term-boundary signals, labelled as forecasts and never attributed to a named board.
How should cyber risk be framed on a Bengaluru healthcare board?
Start with patient care, clinical integrity, privacy and service continuity; technical severity alone does not express the board consequence.
India ID Exchange Foresight
Deploy our search agent before the shortlist is already written
We read 3,790 boards daily, find the roles that fit your committee, sector and geography, and put the brief, fees and deadline in front of you early.
Start ForesightRelated board-seat resources
- Risk Committee Chair Roles in Healthcare and Pharma Industry in Mumbai
- Risk Committee Chair Roles in Healthcare and Pharma Industry in India
- Risk Committee Chair Roles in Financial Services Industry in Bengaluru
- Risk Committee Chair Roles in Technology Industry in Bengaluru
- Risk Committee Chair Roles in Financial Services Industry in Mumbai
- Risk Committee Chair Roles in Technology Industry in Mumbai
- All open board seats on India ID Exchange
- Board Seats in India
- Independent Director Salary Benchmark
- Board Marketplace for Companies
- Independent Director Portfolio Builder
- India ID Exchange Membership Benefits
- Board Readiness Assessment
- Independent Directors in India
Before you apply
What this committee is accountable for, what the seat pays, and how much capacity it will take.